SARS‑CoV‑2 Antibody (IgG), Nucleocapsid, Qualitative
Also known as: COVID, Novel Coronavirus, Wuhan, COVID19, nCOV
Use
This qualitative immunoassay detects IgG antibodies against the SARS‑CoV‑2 nucleocapsid protein in serum (or plasma), serving as an aid to identify individuals who have mounted an adaptive immune response to natural SARS‑CoV‑2 infection (not vaccination alone). It supports assessment of prior or recent infection but is not validated or intended for diagnosing active infection or determining immunity status or post-vaccination response.
Special Instructions
Not provided.
Limitations
This test is qualitative and should not be used to diagnose acute SARS‑CoV‑2 infection. The presence of IgG antibodies does not establish protective immunity or duration of response. A positive result could also reflect cross-reactivity in populations with prior exposure to non‑SARS-CoV‑2 coronaviruses. Antibody response timing may vary, particularly in immunocompromised individuals. Negative results do not rule out infection—molecular testing is indicated if acute infection is suspected.
Methodology
Immunoassay
Biomarkers
SARS‑CoV‑2 IgG nucleocapsid
Protein
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1‑2 mL
Minimum Volume
0.5 mL
Container
Red‑Top Tube
Causes for Rejection
Gross hemolysis; Grossly lipemic; Grossly icteric
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 Days |
| Refrigerated | 7 Days |
| Frozen | 30 Days |
Other tests from different labs that may be relevant